Education
About Us
Working with TipRanks
Follow Us
Scholar Rock Holding Corp (SRRK)
NASDAQ:SRRK
RESEARCH TOOLSreports
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.66Last Year’s EPS
-0.59Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: 4.86%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive outlook for Scholar Rock, with significant progress in its SMA program and commercial preparations for apitegromab. However, there are challenges and uncertainties in the obesity program related to regulatory expectations and the competitive landscape.Company Guidance
During Scholar Rock's Fourth Quarter Financial Results and Business Update Call, the company provided substantial guidance for 2025, emphasizing key metrics and milestones. Scholar Rock is preparing to launch apitegromab, a muscle-targeted therapy, for spinal muscular atrophy (SMA) in the U.S. in the fourth quarter of 2025, with subsequent plans for the EU in 2026. The company reported clinically meaningful and statistically significant improvements in the Hammersmith Functional Motor Scale for SMA patients, with a 1.8-point improvement over placebo. Additionally, 30% of patients achieved a 3-point or greater improvement compared to only 12.5% in the placebo group. Scholar Rock also highlighted the safety profile of apitegromab, with over 95% of patients rolling over into long-term follow-up. For their cardiometabolic program, top-line data for EMBRAZE is anticipated in Q2 2025, and the IND for SRK-439 is expected to be filed in Q3. The company is focusing on preserving lean muscle mass in obesity treatment, targeting a 20% to 40% reduction in loss, potentially translating to a preservation of 1-2 kg of lean mass. These strategic developments align with Scholar Rock's ambition to establish a multibillion-dollar neuromuscular franchise.Successful BLA Submission for Apitegromab
Scholar Rock submitted the Biologics License Application (BLA) for apitegromab in the U.S. in January and is on track to submit the Marketing Authorization Application (MAA) in the EU in March.
Positive Results for Apitegromab in SMA
Apitegromab plus standard-of-care delivered a clinically meaningful and statistically significant improvement of 1.8 points on the Hammersmith Functional Motor scale compared to placebo. 30% of patients achieved an additional 3-point or greater improvement.
Commercial Preparation for Apitegromab Launch
Scholar Rock is preparing for a potential Q4 2025 U.S. launch of apitegromab, with plans to scale the customer-facing team and engage with U.S. commercial and federal payers.
Strong Engagement with SMA Community
Scholar Rock has introduced the 'Life Takes Muscle' campaign to raise awareness and has been engaging with leading CureSMA centers and neurologists.
---
SRRK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SRRK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $37.02 | $35.96 | -2.86% |
| Nov 12, 2024 | $28.15 | $26.66 | -5.29% |
| Aug 08, 2024 | $8.25 | $8.17 | -0.97% |
| May 07, 2024 | $15.06 | $14.69 | -2.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Scholar Rock Holding Corp (SRRK) report earnings?
Scholar Rock Holding Corp (SRRK) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Scholar Rock Holding Corp (SRRK) earnings time?
Scholar Rock Holding Corp (SRRK) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SRRK EPS forecast?
SRRK EPS forecast for the fiscal quarter 2025 (Q1) is -0.66.
---